6.00
price down icon3.54%   -0.22
after-market After Hours: 6.03 0.03 +0.50%
loading
Plus Therapeutics Inc stock is traded at $6.00, with a volume of 175.79K. It is down -3.54% in the last 24 hours and up +80.18% over the past month. Plus Therapeutics Inc is a clinical-stage pharmaceutical company that focuses on discovering, developing, commercializing and delivering complex treatments for patients with cancer and rare diseases. The company is working on a range of potential products, with its main programs targeting recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). One of its key candidates, rhenium (186Re) obisbemeda, is specifically designed to treat central nervous system (CNS) cancers such as GBM, LM, and pediatric brain cancers (PBC).
See More
Previous Close:
$6.22
Open:
$6.05
24h Volume:
175.79K
Relative Volume:
0.05
Market Cap:
$41.17M
Revenue:
$5.21M
Net Income/Loss:
$-26.35M
P/E Ratio:
-0.187
EPS:
-32.0862
Net Cash Flow:
$-20.84M
1W Performance:
+7.14%
1M Performance:
+80.18%
6M Performance:
+1,068%
1Y Performance:
+1,100%
1-Day Range:
Value
$5.83
$6.17
1-Week Range:
Value
$5.5001
$6.6499
52-Week Range:
Value
$0.129
$8.00

Plus Therapeutics Inc Stock (PSTV) Company Profile

Name
Name
Plus Therapeutics Inc
Name
Phone
737.255.7194
Name
Address
4200 MARATHON BLVD., AUSTIN, TX
Name
Employee
28
Name
Twitter
@plustxinc
Name
Next Earnings Date
2026-05-29
Name
Latest SEC Filings
Name
PSTV's Discussions on Twitter

Compare PSTV vs VRTX, REGN, ARGX, ALNY, ONC

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
PSTV icon
PSTV
Plus Therapeutics Inc
6.00 42.68M 5.21M -26.35M -20.84M -32.09
VRTX icon
VRTX
Vertex Pharmaceuticals Inc
427.65 107.87B 12.32B 4.34B 3.19B 16.86
REGN icon
REGN
Regeneron Pharmaceuticals Inc
721.05 73.63B 14.92B 4.42B 3.79B 41.04
ARGX icon
ARGX
Argen X Se Adr
807.55 49.42B 4.16B 1.29B 734.26M 19.58
ALNY icon
ALNY
Alnylam Pharmaceuticals Inc
303.00 40.20B 3.71B 313.75M 465.38M 2.2571
ONC icon
ONC
Beone Medicines Ltd Adr
313.32 33.06B 5.36B 287.73M 924.18M 2.5229

Plus Therapeutics Inc Stock (PSTV) Upgrades & Downgrades

Date Action Analyst Rating Change
Feb-03-26 Initiated Lake Street Buy
Sep-03-25 Upgrade D. Boral Capital Hold → Buy
Mar-17-25 Initiated D. Boral Capital Buy
Jan-25-21 Initiated Ladenburg Thalmann Buy
Oct-16-20 Initiated Maxim Group Buy

Plus Therapeutics Inc Stock (PSTV) Latest News

pulisher
02:36 AM

Plus Therapeutics secures FDA orphan drug status for pediatric glioma treatment - MSN

02:36 AM
pulisher
May 03, 2026

PSTV stock on track for best week since September — here’s what is driving the rally - MSN

May 03, 2026
pulisher
May 01, 2026

PSTV Stock Chart | PLUS THERAPEUTICS INC (NASDAQ:PSTV) - ChartMill

May 01, 2026
pulisher
Apr 30, 2026

Plus Therapeutics Analyst Ratings and Price Targets | NASDAQ:PSTV - Benzinga

Apr 30, 2026
pulisher
Apr 30, 2026

Plus Therapeutics (PSTV) price target decreased by 72.34% to 38.76 - MSN

Apr 30, 2026
pulisher
Apr 29, 2026

Plus Therapeutics, Inc. Income Statement – GETTEX:XMP1 - TradingView

Apr 29, 2026
pulisher
Apr 28, 2026

Plus Therapeutics regains compliance with Nasdaq - MSN

Apr 28, 2026
pulisher
Apr 28, 2026

Plus Therapeutics Secures Blue Shield of California Coverage for CNSide® Cerebrospinal Fluid Assay for Metastatic CNS Cancer - Yahoo Finance

Apr 28, 2026
pulisher
Apr 27, 2026

Plus Therapeutics announces 1-for-25 reverse stock split - MSN

Apr 27, 2026
pulisher
Apr 26, 2026

Why is Plus Therapeutics stock gaining Friday? - MSN

Apr 26, 2026
pulisher
Apr 25, 2026

symbol__ Stock Quote Price and Forecast - CNN

Apr 25, 2026
pulisher
Apr 24, 2026

Plus Therapeutics Inc (PSTV) Stock Price, Quote, News & History - Benzinga

Apr 24, 2026
pulisher
Apr 24, 2026

PSTV Should I Buy - Intellectia AI

Apr 24, 2026
pulisher
Apr 23, 2026

Plus Therapeutics Initiates Manufacturing Activities, Tech Transfer With SpectronRx - Contract Pharma

Apr 23, 2026
pulisher
Apr 23, 2026

Plus Therapeutics Initiates Manufacturing Activities with SpectronRx Under a Master Services Agreement to Support GMP Pivotal Trial Readiness for REYOBIQ™ - The Manila Times

Apr 23, 2026
pulisher
Apr 23, 2026

Plus Therapeutics Initiates Manufacturing Activities with SpectronRx Under a Master Services Agreement to Support GMP Pivotal Trial Readiness for REYOBIQ - ChartMill

Apr 23, 2026
pulisher
Apr 23, 2026

PSTV (PLUS THERAPEUTICS Inc.) reports wider than expected Q4 2025 loss but gains 7.39 percent on optimistic investor outlook.Earnings Surprise - Xã Thanh Hà

Apr 23, 2026
pulisher
Apr 23, 2026

Plus Therapeutics drops 5%, files prospectus for 17M share secondary offering - MSN

Apr 23, 2026
pulisher
Apr 22, 2026

Plus Therapeutics (PSTV) CDO receives new options and RSU grants - Stock Titan

Apr 22, 2026
pulisher
Apr 22, 2026

Plus Therapeutics Reports Granting of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Apr 22, 2026
pulisher
Apr 22, 2026

Plus Therapeutics Regains Nasdaq Listing Compliance After Reverse Split - The Globe and Mail

Apr 22, 2026
pulisher
Apr 21, 2026

PSTV Financials: Income Statement, Balance Sheet & Cash Flow | Plus Therapeutics Inc - Stock Titan

Apr 21, 2026
pulisher
Apr 21, 2026

Plus Therapeutics (PSTV) CDO reports no common stock ownership - Stock Titan

Apr 21, 2026
pulisher
Apr 21, 2026

Plus Therapeutics | 8-K: Current report - Moomoo

Apr 21, 2026
pulisher
Apr 21, 2026

Plus Therapeutics Regains Nasdaq Compliance with Minimum Bid Price Requirement for CNS Cancer Therapies 1 - Minichart

Apr 21, 2026
pulisher
Apr 21, 2026

Plus Therapeutics (PSTV) Meets Nasdaq Bid Price Requirement - GuruFocus

Apr 21, 2026
pulisher
Apr 21, 2026

Plus Therapeutics regains Nasdaq compliance after one-for-25 reverse split - TradingView

Apr 21, 2026

Plus Therapeutics Inc Stock (PSTV) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$28.82
price up icon 1.77%
$50.72
price up icon 0.56%
$95.26
price down icon 0.25%
$137.09
price down icon 1.69%
$151.07
price up icon 2.62%
ONC ONC
$313.32
price up icon 5.32%
Cap:     |  Volume (24h):